shutterstock_572566072_vivi_o
Vivi-o / Shutterstock.com
14 December 2021GenericsAlex Baldwin

Generics win anti-pay-for-delay bill challenge

The Association for Accessible Medicines (AAM), which represents manufacturers of generics and biosimilars, has succeeded in challenging a California bill that characterises “reverse payment” or “pay-for-delay” patent settlements as anticompetitive and unlawful.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

article
11 November 2021   The Federal Trade Commission has stipulated that generic drug marketers ANI Pharmaceuticals, and Novitium Pharma must divest IP rights to Prasco ahead of their $210 million merger.
Generics
6 July 2021   Teva Pharmaceuticals has filed lawsuits in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.
Americas
17 February 2022   A Californian judge has partially revived the state’s pay-for-delay ban after attorney general Rob Bonta requested that a preliminary injunction against the ban be modified.

More on this story

article
11 November 2021   The Federal Trade Commission has stipulated that generic drug marketers ANI Pharmaceuticals, and Novitium Pharma must divest IP rights to Prasco ahead of their $210 million merger.
Generics
6 July 2021   Teva Pharmaceuticals has filed lawsuits in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.
Americas
17 February 2022   A Californian judge has partially revived the state’s pay-for-delay ban after attorney general Rob Bonta requested that a preliminary injunction against the ban be modified.

More on this story

article
11 November 2021   The Federal Trade Commission has stipulated that generic drug marketers ANI Pharmaceuticals, and Novitium Pharma must divest IP rights to Prasco ahead of their $210 million merger.
Generics
6 July 2021   Teva Pharmaceuticals has filed lawsuits in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.
Americas
17 February 2022   A Californian judge has partially revived the state’s pay-for-delay ban after attorney general Rob Bonta requested that a preliminary injunction against the ban be modified.